Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

First Posted Date
2010-09-22
Last Posted Date
2019-04-18
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
50
Registration Number
NCT01206530
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study in Second Line Metastatic Colorectal Cancer

First Posted Date
2010-08-18
Last Posted Date
2019-09-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1072
Registration Number
NCT01183780
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

First Posted Date
2010-08-17
Last Posted Date
2016-06-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
180
Registration Number
NCT01183663
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

First Posted Date
2010-07-16
Last Posted Date
2015-10-09
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
76
Registration Number
NCT01164215
Locations
🇺🇸

Cancer Care of Western North Carolina, Asheville, North Carolina, United States

🇺🇸

Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States

🇺🇸

Marion L. Shepard Cancer Center, Washington, North Carolina, United States

and more 2 locations

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

First Posted Date
2010-06-24
Last Posted Date
2022-03-22
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
2527
Registration Number
NCT01150045
Locations
🇺🇸

Mount Carmel Hospital East, Columbus, Ohio, United States

🇺🇸

Riverside Methodist Hospital, Columbus, Ohio, United States

🇺🇸

Helen F Graham Cancer Center, Newark, Delaware, United States

and more 836 locations

Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

First Posted Date
2010-05-12
Last Posted Date
2014-10-27
Lead Sponsor
Sanofi
Target Recruit Count
108
Registration Number
NCT01121848
Locations
🇨🇦

Investigational Site Number 124011, Greenfield Park, Canada

🇨🇦

Investigational Site Number 124010, Hamilton, Canada

🇨🇦

Investigational Site Number 124008, Sudbury, Canada

and more 12 locations

Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)

First Posted Date
2010-04-13
Last Posted Date
2012-02-23
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
20
Registration Number
NCT01102686
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin

First Posted Date
2010-03-01
Last Posted Date
2014-12-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
75
Registration Number
NCT01077739

Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer

First Posted Date
2010-02-01
Last Posted Date
2017-03-08
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
80
Registration Number
NCT01060007
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

First Posted Date
2010-01-12
Last Posted Date
2014-09-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
49
Registration Number
NCT01046864
Locations
🇺🇸

Scott & White Memorial Hospital And Clinic, Temple, Texas, United States

🇺🇸

Texas Oncology, Dallas, Texas, United States

🇺🇸

Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy